March 31st 2017 Hong Kong, PRC – Luqa Pharmaceuticals (“Luqa” or the “Company”), the China focused specialty pharmaceutical company, announces that it has entered into an exclusive long-term agreement for the distribution rights of MACMIROR (Nifuratel).

MACMIROR (Nifuratel) is a product used for the polyvalent therapy of vulvovaginal infections due to pathogenic micro-organisms: Candida, Trichomonas and Bacteria. The product is used in the treatment of a wide range of infections of the genito-urinary tract.

The product is already registered in the Peoples Republic of China and Luqa will be responsible for the sales, marketing and distribution, with initial commercialization expected during the second half of 2017. Luqa is already firmly established in the women’s health market with both its prescription and aesthetic dermatology portfolio, which is actively promoted and distributed by the Company’s own sales force across China.

Robert Braithwaite, Luqa’s CEO commented,

“Coming after our recent acquisition of Arista- which expanded our commercial footprint in China, we are very pleased to announce this transaction, which extends Luqa’s growing women’s health portfolio with the commercial rights for a registered prescription drug, used in various public and private hospital settings”.


About Luqa
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty segments in China.

For more information about Luqa Pharmaceuticals
Mr. Luis Juste
Business Development Director

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to present and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.

Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2.000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

For more information, please visit